Chromosome Xq23 is associated with lower atherogenic lipid concentrations and favorable cardiometabolic indices
- PMID: 33846329
- PMCID: PMC8042019
- DOI: 10.1038/s41467-021-22339-1
Chromosome Xq23 is associated with lower atherogenic lipid concentrations and favorable cardiometabolic indices
Abstract
Autosomal genetic analyses of blood lipids have yielded key insights for coronary heart disease (CHD). However, X chromosome genetic variation is understudied for blood lipids in large sample sizes. We now analyze genetic and blood lipid data in a high-coverage whole X chromosome sequencing study of 65,322 multi-ancestry participants and perform replication among 456,893 European participants. Common alleles on chromosome Xq23 are strongly associated with reduced total cholesterol, LDL cholesterol, and triglycerides (min P = 8.5 × 10-72), with similar effects for males and females. Chromosome Xq23 lipid-lowering alleles are associated with reduced odds for CHD among 42,545 cases and 591,247 controls (P = 1.7 × 10-4), and reduced odds for diabetes mellitus type 2 among 54,095 cases and 573,885 controls (P = 1.4 × 10-5). Although we observe an association with increased BMI, waist-to-hip ratio adjusted for BMI is reduced, bioimpedance analyses indicate increased gluteofemoral fat, and abdominal MRI analyses indicate reduced visceral adiposity. Co-localization analyses strongly correlate increased CHRDL1 gene expression, particularly in adipose tissue, with reduced concentrations of blood lipids.
Conflict of interest statement
P.N. reports grants from Amgen, Apple, Boston Scientific, and Novartis, and consulting income from Apple, Blackstone Life Sciences, Genentech, and Novartis. S.L. reports grants from Bristol Myers Squibb / Pfizer, Bayer AG, and Boehringer Ingelheim, and consulting income from Bristol Myers Squibb / Pfizer and Bayer AG. P.E. is supported by a grant from Bayer AG to the Broad Institute focused on the genetics and therapeutics of cardiovascular diseases. P.E. reports consulting income from Bayer AG, Quest Diagnostics, and Novartis. All others declare no competing interests for the present work.
Figures



References
-
- Brown MS, Goldstein JL. Familial hypercholesterolemia: defective binding of lipoproteins to cultured fibroblasts associated with impaired regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity. Proc. Natl Acad. Sci. USA. 1974;71:788–792. doi: 10.1073/pnas.71.3.788. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- T32 HL094301/HL/NHLBI NIH HHS/United States
- R01 HL139731/HL/NHLBI NIH HHS/United States
- U19 CA203654/CA/NCI NIH HHS/United States
- R35 HL135824/HL/NHLBI NIH HHS/United States
- T32 HG000040/HG/NHGRI NIH HHS/United States
- R01 HL105756/HL/NHLBI NIH HHS/United States
- K08 HL140203/HL/NHLBI NIH HHS/United States
- P30 DK072488/DK/NIDDK NIH HHS/United States
- R03 HL154284/HL/NHLBI NIH HHS/United States
- R01 HL117626/HL/NHLBI NIH HHS/United States
- R01 HL148050/HL/NHLBI NIH HHS/United States
- K01 HL135405/HL/NHLBI NIH HHS/United States
- R01 HL120393/HL/NHLBI NIH HHS/United States
- R01 HL046380/HL/NHLBI NIH HHS/United States
- R03 HL141439/HL/NHLBI NIH HHS/United States
- R01 HL109946/HL/NHLBI NIH HHS/United States
- K01 AG059898/AG/NIA NIH HHS/United States
- R01 HL148565/HL/NHLBI NIH HHS/United States
- R01 HL113338/HL/NHLBI NIH HHS/United States
- K01 HL125751/HL/NHLBI NIH HHS/United States
- T32 HL007208/HL/NHLBI NIH HHS/United States
- R01 HL142711/HL/NHLBI NIH HHS/United States
- R35 HL135818/HL/NHLBI NIH HHS/United States